Gentian Diagnostics ASA has unveiled promising findings from its latest research at EuroMedLab 2025 in Brussels. The company presented two scientific posters focusing on innovative diagnostic assays. The NT-proBNP assay, currently in development, introduces a novel approach to heart failure detection by targeting glycosylation-free regions of the NT-proBNP molecule. This approach aims to provide more accurate assessments by overcoming glycosylation bias, which traditionally hampers antibody binding. The Gentian proto-type assay demonstrated strong analytical performance and compatibility with major instrument platforms, such as Mindray and Beckman Coulter. Meanwhile, the Retinol-Binding Protein (RBP) assay focuses on nutritional status evaluation and renal function assessment. The study established a comprehensive reference range using the Beckman Coulter DxC 700 AU Analyzer, highlighting RBP's dual role as a biomarker for vitamin A deficiency and renal dysfunction. Gentian's research emphasizes the importance of assay-specific validation to ensure accurate clinical interpretation, marking significant advancements in diagnostic workflows.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.